Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 October 2018Website:
http://www.revivapharma.comNext earnings report:
21 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 23:24:12 GMTDividend
Analysts recommendations
Institutional Ownership
RVPH Latest News
– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – CUPERTINO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended September 30, 2024 and summarized recent business highlights.
CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually October 15-17, 2024.
CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 3rd Annual ROTH Healthcare Opportunities Conference, taking place October 9, 2024, in New York, NY.
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD)
NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present new efficacy data on brilaroxazine in an animal model of idiopathic pulmonary fibrosis at the 2024 American Thoracic Society International Conference in San Diego, CA on May 17-22, 2024.
CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present at the Webull LIVE!
Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo on the primary endpoint. The 15 mg dose of brilaroxazine was numerically superior to placebo on the primary endpoint, but did not reach significance. Reviva Pharmaceuticals plans to start its second phase 3 study, RECOVER-2, in Q1'24 and will need to raise additional funds to support the study.
Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study.
Reviva Pharmaceuticals is running a phase 3 study of brilaroxazine in schizophrenia called RECOVER, with results expected in October 2023. A previous phase 2 study showed that brilaroxazine had significant antipsychotic activity, and a potentially differentiated side effect profile versus Abilify. RVPH had $11.2M in cash and cash equivalents at the end of Q2'23, and could fall heavily if the phase 3 study doesn't succeed.
What type of business is Reviva Pharmaceuticals Holdings?
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
What sector is Reviva Pharmaceuticals Holdings in?
Reviva Pharmaceuticals Holdings is in the Healthcare sector
What industry is Reviva Pharmaceuticals Holdings in?
Reviva Pharmaceuticals Holdings is in the Biotechnology industry
What country is Reviva Pharmaceuticals Holdings from?
Reviva Pharmaceuticals Holdings is headquartered in United States
When did Reviva Pharmaceuticals Holdings go public?
Reviva Pharmaceuticals Holdings initial public offering (IPO) was on 18 October 2018
What is Reviva Pharmaceuticals Holdings website?
https://www.revivapharma.com
Is Reviva Pharmaceuticals Holdings in the S&P 500?
No, Reviva Pharmaceuticals Holdings is not included in the S&P 500 index
Is Reviva Pharmaceuticals Holdings in the NASDAQ 100?
No, Reviva Pharmaceuticals Holdings is not included in the NASDAQ 100 index
Is Reviva Pharmaceuticals Holdings in the Dow Jones?
No, Reviva Pharmaceuticals Holdings is not included in the Dow Jones index
When was Reviva Pharmaceuticals Holdings the previous earnings report?
No data
When does Reviva Pharmaceuticals Holdings earnings report?
The next expected earnings date for Reviva Pharmaceuticals Holdings is 21 November 2024